OncoDNA, MyNEO partner on personalized cancer vaccines

By The Science Advisory Board staff writers

April 7, 2021 -- OncoDNA and MyNEO will collaborate on the production of personalized cancer vaccines for patients who have run out of treatment options.

The companies will use their sequencing and bioinformatics technologies to identify and select the most effective neoantigens to target in a patient. OncoDNA will perform whole genome and whole transcriptome sequencing, and MyNEO will handle the advanced interpretation of the sequenced data and design the vaccine construct. Eligible patients would receive tailor-made vaccines and follow-up by monitoring circulating tumor DNA after inoculation using OncoDNA's OncoFollow liquid biopsy platform.

Copyright © 2021 scienceboard.net

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a Scienceboard.net password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?